초록 ▼

A mammalian blood protein-containing composition such as whole blood, plasma, serum, plasma concentrate, cryoprecipitate, cryosupernatant, plasma fractionation precipitate or plasma fractionation supernatant substantially free of hepatitis and other lipid coated viruses with the yield of protein act

A mammalian blood protein-containing composition such as whole blood, plasma, serum, plasma concentrate, cryoprecipitate, cryosupernatant, plasma fractionation precipitate or plasma fractionation supernatant substantially free of hepatitis and other lipid coated viruses with the yield of protein activity to total protein being at least 80% is disclosed. The protein-containing composition is contacted with di- or trialkylphosphate, preferably a mixture of trialkylphosphate and detergent, usually followed by removal of the di- or trialkylphosphate.

대표청구항 ▼

1. A process for rendering a blood product which comprises a labile blood protein substantially free of lipid-containing viruses without incurring substantial protein denaturation which comprises contacting said blood product with an effective amount of a di- or trialkylphosphate for a period of tim

1. A process for rendering a blood product which comprises a labile blood protein substantially free of lipid-containing viruses without incurring substantial protein denaturation which comprises contacting said blood product with an effective amount of a di- or trialkylphosphate for a period of time sufficient to render said blood product substantially free of lipid-containing viruses without incurring substantial protein denaturation. 2. A process according to claim 1 wherein di- or trialkylphosphate has alkyl groups which contain 1 to 10 carbon atoms. 3. A process according to claim 2 wherein said trialkylphosphate has alkyl groups which contain 2 to 10 carbon atoms. 4. A process according to claim 2 wherein said trialkylphosphate is tri-n-butyl phosphate. 5. A process according to claim 1 wherein said contacting is conducted in the presence of a wetting agent. 6. A process according to claim 5 wherein said wetting agent is a non-ionic detergent. 7. A process according to claim 5 wherein said wetting agent is added to said blood product prior to contacting said blood product with said di- or trialkylphosphate. 8. A process according to claim 5 wherein said wetting agent is added simultaneously with said di- or trialkylphosphate to said blood product. 9. A process according to claim 5 wherein said wetting agent is added after said di- or trialkylphosphate contacts said blood product. 10. A process according to claim 6 wherein said detergent is a partial ester of sorbitol anhydrides. 11. A process according to claim 1 further comprising conducting said contacting in the presence of lipid coated virus inactivating agent selected from the group consisting of ethers and alcohols. 12. A process according to claim 5 further comprising conducting said contacting in the presence of an inactivating agent selected from the group consisting of ethers and alcohols. 13. A process according to claim 1 wherein said blood protein is selected from the group consisting of whole blood, blood plasma, red blood cells, leucocytes, platelet concentrates, a plasma concentrate, a precipitate from any fractionation of such plasma, a supernatant from any fractionation of said plasma, a serum, a cryoprecipitate, a cell lysate and proteins induced in blood cells. 14. A process according to claim 1 wherein said labile blood protein is selected from the group consisting of fibrinogen, cold insoluble globulin, properdin, IgG, IgM, IgA, betaliproprotein, plasmin-inhibitor, factor V, thrombin, antithrombin, isoagglutinins, cerutoplasmin, alpha 1 -lipoprotein, peptidase, transferrin, thyroxine binding globulin, serum esterase, alkaline phosphates, alpha 1 -acid glycoprotein, factor II, factor VII, factor VIII, factor IX, factor X, factor XIII, factor I, immunoglobulins, prealbumin, retinol-binding protein, albumin, alpha-globulins, beta-globulins, gamma-globulins, factor III, the complement components, fibronectin, antithrombin III, hemoglobin, interferon, T-cell growth factor and plasminogen activator. 15. A process according to claim 1 wherein following said contacting with said di- or trialkylphosphate, said di- or trialkylphosphate is removed. 16. A process according to claim 1 wherein said period of time is between about 1 minute and about 30 hours. 17. A process according to claim 1 wherein said contacting is conducted at a temperature of between about 0° C. and about 70° C. 18. A process according to claim 1 wherein said di- or trialkylphosphate is present in an amount between about 0.001% and about 1%. 19. A process according to claim 13 wherein said blood product comprises factor VIII. 20. A process according to claim 13 wherein said blood product comprises factor IX. 21. A process according to claim 1 wherein said blood product is additionally heated for at least 5 hours at 50° to 70° C. 22. A process according to claim 22 wherein the composition which is heated comprises a protein stabilizer which stabilizes a protein against denaturation by heat. 23. A process according to claim 1 wherein said labile blood protein is factor VIII. 24. A process according to claim 1 wherein said labile blood protein is factor VII. 25. A process according to claim 1 wherein said labile blood protein is factor IX. 26. A process according to claim 1 wherein said labile blood protein is factor X. 27. A process according to claim 1 wherein said labile blood protein is fibrinogen. 28. A process according to claim 1 wherein said labile blood protein is fibronectin. 29. A process according to claim 1 wherein said labile blood protein comprises an antibody against infectious hepatitis. 30. A process according to claim 1 wherein said labile blood protein is factor XIII. 31. A process according to claim 1 wherein said labile blood protein is T-cell growth factor. 32. A process according to claim 1 wherein said labile blood protein is a protein of a leucocyte. 33. A process according to claim 1 wherein said labile blood protein is a protein of a red blood cell. 34. A process according to claim 1 wherein said labile blood protein is a protein of a blood platelet concentrate.